Salim Syed
Stock Analyst
(2.19)
# 4,648
Out of 4,648 analysts
71
Total ratings
35.71%
Success rate
-0.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $106.49 | +53.07% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $11.63 | +54.77% | 4 | Aug 16, 2024 | |
| BIIB Biogen | Maintains: Outperform | $277 → $251 | $173.52 | +44.65% | 14 | Aug 6, 2024 | |
| WVE Wave Life Sciences | Reiterates: Outperform | $19 | $13.79 | +37.78% | 4 | Jun 25, 2024 | |
| AMGN Amgen | Maintains: Neutral | $223 → $235 | $316.91 | -25.85% | 7 | May 9, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $27.65 | +22.97% | 1 | Apr 9, 2024 | |
| NKTX Nkarta | Maintains: Buy | $31 → $25 | $3.23 | +673.99% | 6 | Mar 22, 2024 | |
| CYTK Cytokinetics | Maintains: Buy | $103 → $99 | $51.48 | +92.31% | 5 | Mar 6, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $50.59 | +95.69% | 3 | Mar 6, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $53 | $25.20 | +110.32% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $90 | $89.84 | +0.18% | 5 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $1.26 | +376.19% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $0.67 | +3,034.33% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $16.98 | +112.01% | 1 | Nov 16, 2022 |
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $106.49
Upside: +53.07%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $11.63
Upside: +54.77%
Biogen
Aug 6, 2024
Maintains: Outperform
Price Target: $277 → $251
Current: $173.52
Upside: +44.65%
Wave Life Sciences
Jun 25, 2024
Reiterates: Outperform
Price Target: $19
Current: $13.79
Upside: +37.78%
Amgen
May 9, 2024
Maintains: Neutral
Price Target: $223 → $235
Current: $316.91
Upside: -25.85%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $27.65
Upside: +22.97%
Nkarta
Mar 22, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $3.23
Upside: +673.99%
Cytokinetics
Mar 6, 2024
Maintains: Buy
Price Target: $103 → $99
Current: $51.48
Upside: +92.31%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $50.59
Upside: +95.69%
BridgeBio Pharma
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $25.20
Upside: +110.32%
Feb 22, 2024
Maintains: Buy
Price Target: $101 → $90
Current: $89.84
Upside: +0.18%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $1.26
Upside: +376.19%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $0.67
Upside: +3,034.33%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $16.98
Upside: +112.01%